Praxis Precision Medicines (PRAX) Set to Announce Earnings on Wednesday

Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) will issue its quarterly earnings data before the market opens on Wednesday, November 6th. Analysts expect the company to announce earnings of ($2.01) per share for the quarter. Persons that wish to register for the company's earnings conference call can do so using this link.

Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($1.74) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.38) by $0.64. The firm had revenue of $0.36 million during the quarter, compared to the consensus estimate of $1.44 million. Praxis Precision Medicines had a negative return on equity of 61.47% and a negative net margin of 6,987.01%. On average, analysts expect Praxis Precision Medicines to post $-9 EPS for the current fiscal year and $-9 EPS for the next fiscal year.

Praxis Precision Medicines Trading Down 2.4 %

Shares of Praxis Precision Medicines stock traded down $1.66 during trading hours on Friday, reaching $68.33. The stock had a trading volume of 205,786 shares, compared to its average volume of 235,586. The firm has a market capitalization of $1.21 billion, a price-to-earnings ratio of -6.67 and a beta of 2.67. Praxis Precision Medicines has a 1 year low of $13.01 and a 1 year high of $75.73. The firm has a 50 day simple moving average of $62.58 and a two-hundred day simple moving average of $53.23.

Wall Street Analyst Weigh In

PRAX has been the topic of several research reports. HC Wainwright restated a "buy" rating and issued a $120.00 price target on shares of Praxis Precision Medicines in a report on Tuesday, September 10th. Needham & Company LLC restated a "buy" rating and set a $145.00 target price on shares of Praxis Precision Medicines in a report on Tuesday, September 3rd. Guggenheim increased their price target on Praxis Precision Medicines from $155.00 to $170.00 and gave the company a "buy" rating in a report on Wednesday, August 14th. Oppenheimer raised their price objective on Praxis Precision Medicines from $143.00 to $163.00 and gave the company an "outperform" rating in a research report on Thursday. Finally, Wedbush upped their target price on Praxis Precision Medicines from $40.00 to $48.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 14th. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, Praxis Precision Medicines has an average rating of "Moderate Buy" and a consensus target price of $145.67.

Praxis Precision Medicines Company Profile

Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.